Updated:
HotSpot Therapeutics
HotSpot Therapeutics is a Boston-based biotechnology firm founded in 2017. It focuses on developing allosteric therapies for novel disease treatments.
HotSpot Therapeutics
HotSpot Therapeutics is a Boston-based biotechnology firm founded in 2017. It focuses on developing allosteric therapies for novel disease treatments. The company has secured $210 million in total funding.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Sector focus
Frequently asked questions
What is HotSpot Therapeutics' drug discovery platform?
HotSpot Therapeutics uses its proprietary SmartAllostery platform to identify and target allosteric binding sites on proteins. This approach aims to modulate protein function with high specificity, potentially addressing targets considered undruggable by conventional methods (per public records).
Which therapeutic areas does HotSpot Therapeutics focus on?
The company's pipeline is centered on immunology and oncology. Public disclosures indicate programs for autoimmune diseases and solid tumors, though specific development stages are not fully detailed (per public records).
How is HotSpot Therapeutics funded?
HotSpot has raised venture capital financing, including Series A and B rounds with participation from investors like SR One and Google Ventures, per public announcements. The firm does not disclose current AUM or operating budget.
Who are the key executives at HotSpot Therapeutics?
Named executives are not publicly disclosed on the firm's website or in known public records. The team is described as having experience in large pharmaceutical and biotechnology companies.
Is HotSpot Therapeutics structured as a family office or investment firm?
HotSpot Therapeutics operates as a biotechnology company, not a family office or investment manager. Its primary activity is drug discovery and development, not capital management.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: